Nkizinkiko Yves, Suneel Kumar B V S, Jeankumar Variam Ullas, Haikarainen Teemu, Koivunen Jarkko, Madhuri Chanduri, Yogeeswari Perumal, Venkannagari Harikanth, Obaji Ezeogo, Pihlajaniemi Taina, Sriram Dharmarajan, Lehtiö Lari
Faculty of Biochemistry and Molecular Medicine & Biocenter Oulu, University of Oulu, PO Box 5400, FIN-90014 Oulu, Finland.
Department of Pharmacy at Birla Institute of Technology and Science-Pilani, Hyderabad campus, Hyderabad 500078, India.
Bioorg Med Chem. 2015 Aug 1;23(15):4139-4149. doi: 10.1016/j.bmc.2015.06.063. Epub 2015 Jul 2.
Diphtheria toxin-like ADP-ribosyltransferases catalyse a posttranslational modification, ADP-ribosylation and form a protein family of 17 members in humans. Two of the family members, tankyrases 1 and 2, are involved in several cellular processes including mitosis and Wnt/β-catenin signalling pathway. They are often over-expressed in cancer cells and have been linked with the survival of cancer cells making them potential therapeutic targets. In this study, we identified nine tankyrase inhibitors through virtual and in vitro screening. Crystal structures of tankyrase 2 with the compounds showed that they bind to the nicotinamide binding site of the catalytic domain. Based on the co-crystal structures we designed and synthesized a series of tetrahydroquinazolin-4-one and pyridopyrimidin-4-one analogs and were subsequently able to improve the potency of a hit compound almost 100-fold (from 11 μM to 150 nM). The most potent compounds were selective towards tankyrases over a panel of other human ARTD enzymes. They also inhibited Wnt/β-catenin pathway in a cell-based reporter assay demonstrating the potential usefulness of the identified new scaffolds for further development.
类白喉毒素 ADP 核糖基转移酶催化一种翻译后修饰——ADP 核糖基化,在人类中形成一个由 17 个成员组成的蛋白质家族。该家族中的两个成员,端锚聚合酶 1 和 2,参与包括有丝分裂和 Wnt/β - 连环蛋白信号通路在内的多种细胞过程。它们在癌细胞中常常过度表达,并与癌细胞的存活有关,使其成为潜在的治疗靶点。在本研究中,我们通过虚拟筛选和体外筛选鉴定出了 9 种端锚聚合酶抑制剂。端锚聚合酶 2 与这些化合物的晶体结构表明,它们结合在催化结构域的烟酰胺结合位点。基于共晶体结构,我们设计并合成了一系列四氢喹唑啉 -4- 酮和吡啶并嘧啶 -4- 酮类似物,随后能够将一种活性化合物的效力提高近 100 倍(从 11 μM 提高到 150 nM)。最有效的化合物对端锚聚合酶具有选择性,优于其他一系列人类 ADP 核糖基转移酶结构域蛋白。它们还在基于细胞的报告基因检测中抑制了 Wnt/β - 连环蛋白信号通路,证明了所鉴定的新支架用于进一步开发的潜在用途。